Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Molecular Medicine Congress

Klaus Pantel's Biography



Klaus Pantel, Chairman, Department of Tumor Biology, University Medical Center Hamburg-Eppendorf

Prof. Klaus Pantel graduated in 1986 from Cologne University in Germany and completed his thesis on mathematical modelling of hematopoiesis in 1987. After his postdoctoral period in the USA on hematopoietic stem cell regulation (Wayne State University, Detroit), he performed research on cancer micrometastasis at the Institute of Immunology, University of Munich for 10 years. Currently, Prof Pantel is Chairman of the Institute of Tumour Biology at the University Medical Center Hamburg-Eppendorf. The institute is part of the University Cancer Center Hamburg (UCCH). The pioneer work of Prof Pantel in the field of cancer micrometastasis, circulating tumor cells and circulating nucleic acids (ctDNA, microRNAs) is reflected by more than 300 publications in excellent high ranking biomedical and scientific journals (incl. NEJM, Lancet, Nature Journals, Cancer Cell, PNAS, JCO, JNCI, Cancer Res.) and has been awarded recently (AACR Outstanding Investigator Award 2010, German Cancer Award 2010, ERC Advanced Investigator Grant 2011). Moreover, Prof Pantel was co-ordinator of the FP6 EU STREP “DISMAL” (Disseminated Malignancies, www.dismal-project.eu), coordinates now the European TRANSCAN group “CTC-SCAN” and the EU IMI Network Project “CANCER-ID” (www.cancer-id.eu) and serves on the Editorial Boards of international cancer journals (e.g., Clin. Cancer Res., Breast Cancer Res., Cancer Res.).

Klaus Pantel Image

Detection and Clinical Implications of Circulating Tumor Cells in Cancer Patients

Tuesday, 3 September 2013 at 08:30

Add to Calendar ▼2013-09-03 08:30:002013-09-03 09:30:00Europe/LondonDetection and Clinical Implications of Circulating Tumor Cells in Cancer PatientsMolecular Medicine Congress in Frankfurt, GermanyFrankfurt, GermanySELECTBIOenquiries@selectbiosciences.com

Detection and characterization of CTC opens a new avenue for understanding metastatic spread of tumor cells with important implications for future therapies. Implementation of CTC analyses in clinical trials testing new anti-cancer agents as companion diagnostics will speed up the cumbersome and expensive drug validation process in oncology.


Add to Calendar ▼2013-09-03 00:00:002013-09-04 00:00:00Europe/LondonMolecular Medicine CongressMolecular Medicine Congress in Frankfurt, GermanyFrankfurt, GermanySELECTBIOenquiries@selectbiosciences.com